SGMT Sagimet Biosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1400118 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-26.0%
ROIC (approx.)-43.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio6.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $16.34M | $11.54M | $7.00M | $6.73M | $9.73M | $7.25M | $15.34M | $14.22M |
| SG&A expense | $5.23M | $4.28M | $4.72M | $4.03M | $4.60M | $4.68M | $4.52M | $3.98M |
| Operating income | -$21.57M | -$15.82M | -$11.71M | -$10.77M | -$14.33M | -$11.93M | -$19.86M | -$18.20M |
| Net income | -$19.15M | -$13.95M | -$10.65M | -$9.57M | -$12.91M | -$10.39M | -$18.18M | -$16.20M |
| EPS (basic) | -0.31 | -0.26 | -0.33 | — | -0.40 | -0.32 | -0.56 | — |
| EPS (diluted) | -0.31 | -0.26 | -0.33 | — | -0.40 | -0.32 | -0.56 | — |
| Weighted avg. shares (diluted) | 62.34M | 53.11M | 32.56M | — | 32.46M | 32.20M | 32.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $110.96M | $165.90M | $36.63M | $35.02M | $32.50M | $42.33M | $64.72M | $75.84M |
| Short-term investments | $125.44M | $74.23M | $67.91M | $78.10M | $84.20M | $83.08M | $79.85M | $75.41M |
| Current assets | $240.72M | $243.99M | $107.72M | $116.40M | $119.48M | $127.20M | $146.07M | $152.77M |
| Total assets | $282.09M | $263.43M | $107.75M | $116.48M | $128.40M | $137.41M | $146.17M | $160.26M |
| Current liabilities | $37.98M | $5.42M | $5.30M | $5.10M | $9.15M | $7.25M | — | $4.45M |
| Total liabilities | $39.91M | $7.28M | $5.30M | $5.10M | $9.15M | $7.25M | $7.18M | $4.45M |
| Shareholders' equity | $242.18M | $256.15M | $102.46M | $111.38M | $119.25M | $130.16M | $138.99M | $155.81M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.11M | -$11.10M | -$8.61M | -$11.83M | -$10.18M | -$9.10M | -$14.54M | -$11.02M |
| Investing cash flow | -$73.25M | -$24.02M | $10.22M | $14.36M | $75,000 | -$13.29M | $3.41M | $9.85M |
| Financing cash flow | $30.43M | — | — | $0 | $274,000 | — | — | $0 |
| Stock-based compensation | $2.39M | $3.69M | $1.84M | $1.69M | $1.69M | $1.60M | $1.47M | $1.53M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.